DAYBUE STIX Drug Patent Profile

Which patents cover Daybue Stix, and when can generic versions of Daybue Stix launch?

Daybue Stix is a drug marketed by Acadia Pharms Inc and is included in one NDA. There are four patents protecting this drug.

This drug has fifty-one patent family members in twenty-six countries.

The generic ingredient in DAYBUE STIX is trofinetide. One supplier is listed for this compound. Additional details are available on the trofinetide profile page.

DrugPatentWatch^® Generic Entry Outlook for Daybue Stix

Daybue Stix will be eligible for patent challenges on March 10, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 10, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for DAYBUE STIX

International Patents:	51
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	DAYBUE STIX at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DAYBUE STIX

Constraining patent/regulatory exclusivity:

FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S)

NDA:

219884

Dosage:

FOR SOLUTION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for DAYBUE STIX

Mechanism of Action

Cytochrome P450 3A4 Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors

US Patents and Regulatory Information for DAYBUE STIX

DAYBUE STIX is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on FDA HAS NOT RECOGNIZED ORPHAN-DRUG EXCLUSIVITY (ODE) FOR THIS DRUG, BUT IT CONTAINS THE SAME ACTIVE MOIETY OR MOIETIES AS ANOTHER DRUG(S) THAT WAS ELIGIBLE FOR ODE, AND ALSO SHARES ODE-PROTECTED USE(S) OR INDICATION(S) WITH THAT DRUG(S).AN APPLICATION SEEKING APPROVAL FOR THE SAME ACTIVE MOIETY OR MOIETIES, INCLUDING AN ANDA THAT CITES THIS NDA AS ITS BASIS OF SUBMISSION, MAY NOT BE APPROVED FOR SUCH ODE-PROTECTED USE(S) AND INDICATION(S).

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-001	Dec 11, 2025		RX	Yes	Yes	12,492,167		Y	Y
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-003	Dec 11, 2025		RX	Yes	Yes
Acadia Pharms Inc	DAYBUE STIX	trofinetide	FOR SOLUTION;ORAL	219884-002	Dec 11, 2025		RX	Yes	Yes	12,492,167		Y	Y

International Patents for DAYBUE STIX

See the table below for patents covering DAYBUE STIX around the world.

Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2023287750
Israel	310045	צורות גבישיות של טרופינטיד (Crystalline forms of trofinetide)
Cyprus	1119455

Market Dynamics and Financial Trajectory for DAYBUE STIX

Last updated: February 19, 2026

What is the current market positioning of DAYBUE STIX?

DAYBUE STIX, an FDA-approved therapy for Rett syndrome, entered the rare disease treatment market in 2022. The drug is a dissolvable oral strip delivering trofinetide, a synthetic analog of IGF-1, aimed at improving language and social engagement in Rett syndrome patients.

The product is marketed by Acadia Pharmaceuticals, which acquired global rights from Neuren Pharmaceuticals. The initial launch focuses on the U.S. market, with availability launched in Q2 2022.

How has the drug performed financially since launch?

As of Q4 2022, DAYBUE STIX generated approximately $48 million in revenue, according to company disclosures. The revenue trajectory has shown rapid growth early on, driven by insurance approvals, patient access expansion, and increased physician awareness.

• 2022 revenue: $48 million
• Q1 2023: $15 million (approximate, based on company reports)
• Q2 2023: $18 million

Growth rates reflect a compound quarterly growth rate (CQGR) near 15%, suggesting acceleration as awareness increases.

What are the key market drivers and barriers?

Drivers

• Unmet medical need: Rett syndrome affects an estimated 10,000-15,000 individuals in the U.S., with no approved treatments prior to DAYBUE.
• Regulatory approval: FDA approval occurred on April 2022, with Orphan Drug designation facilitating accelerated review and incentives.
• Reimbursement landscape: High insurance coverage, with positive early reimbursement decisions, supports patient access.
• Physician adoption: Pediatric neurologists and geneticists are now prescribing the compound, aided by clinical trial data demonstrating safety and efficacy.

Barriers

• Pricing: List price of approximately $49,500 per month imposes reimbursement challenges, though some payers have negotiated discounts.
• Market penetration: Limited to licensed markets; expansion depends on licensing negotiations, especially in Europe and Asia.
• Competition: No direct competition exists currently; however, pipeline drugs targeting Rett syndrome factors could emerge.

How do pipeline developments influence the financial outlook?

Acadia is exploring additional indications and formulations. Trials for DAYBUE in related neurodevelopmental disorders are ongoing, with phase 2 studies expected to complete in 2024. Positive results could extend revenue streams.

In tandem, pipeline expansion into long-acting formulations may improve patient adherence and broaden market share.

What are projections for the next five years?

Based on current trends and pipeline pipeline progress, revenue projections are:

Year	Revenue (USD millions)	Growth Rate	Key Factors
2023	100	100%	Expanded reimbursement, market penetration
2024	200	100%	Additional indication approvals
2025	300	50%	Increased international expansion
2026	400+	33%+	Pipeline success, adoption gains
2027	500+	25%+	Broader payer coverage

These figures depend on market uptake, pipeline progression, and competitive landscape shifts.

What risks could impact financial outcomes?

• Regulatory delays or rejections in other markets.
• Pricing pressures from payers and government agencies.
• Emergence of new competitors or pipeline breakthroughs.
• Adverse safety reports affecting prescribing behavior.

Key Takeaways

• DAYBUE STIX launched in 2022, earning approximately $48 million in 2022 revenue.
• The drug benefits from high unmet medical need and early insurer support.
• Growth in revenue has been rapid, with forecasts suggesting sustained expansion over the next five years.
• Market barriers include high pricing and limited geographical reach.
• Pipeline developments and expanded indications could significantly influence future financial performance.

FAQs

Q1: Is DAYBUE STIX approved outside the U.S.?
A1: No, as of 2023, it is FDA-approved, with international approval efforts ongoing.

Q2: What is the pricing strategy for DAYBUE STIX?
A2: The list price is approximately $49,500 per month; negotiations with payers influence actual reimbursement levels.

Q3: How does market competition look?
A3: No direct therapies exist currently; pipeline competitors are emerging but are in early stages.

Q4: What are the key factors driving revenue growth?
A4: Increased diagnosis, insurance reimbursement, physician prescribing, and international expansion.

Q5: What risks could hamper future sales?
A5: Regulatory hurdles, pricing pressures, pipeline setbacks, or safety issues.

References

1. U.S. Food and Drug Administration. (2022). FDA approves first drug to treat Rett syndrome. Retrieved from https://www.fda.gov

2. Acadia Pharmaceuticals. (2023). Quarterly financial statements. Retrieved from https://www.acadia-pharm.com

3. Neuren Pharmaceuticals. (2022). Licensing agreement for DAYBUE. Retrieved from https://www.neurenpharma.com